Loading...
XKRX
011000
Market cap36mUSD
Jul 22, Last price  
2,670.00KRW
Name

Gene One Life Science Inc

Chart & performance

D1W1MN
XKRX:011000 chart
P/E
—
P/S
2.02
EPS
—
Div yield, %
—
Shrs. gr., 5y
-25.01%
Rev. gr., 5y
-10.43%
Revenues
23.93b
-33.00%
10,090,159,00013,974,021,00015,003,954,00023,281,689,00027,737,197,30019,410,461,05020,657,215,57024,625,225,86028,364,784,67031,371,459,15027,171,385,67034,292,567,64041,241,251,00041,502,728,97038,700,355,00048,718,300,00040,202,911,00035,720,099,00023,931,169,000
Net income
-47.66b
L-1.80%
-2,902,726,000-5,849,328,000-8,415,948,000-7,592,468,000-4,937,077,000-8,888,478,000-8,362,870,000-6,491,730,0001,413,762,890-15,598,929,630-23,729,654,920-11,897,642,780-7,618,563,000-18,648,412,110-15,951,500,000-38,150,070,000-77,768,042,000-48,536,607,000-47,662,169,000
CFO
-16.52b
L+2.90%
-3,269,203,000-3,147,292,000-3,040,938,000-3,876,427,000-2,874,458,200-6,202,869,980-2,347,273,130-4,158,524,800778,497,730-12,388,731,200-4,040,042,510-7,268,957,370-1,270,007,140-15,915,810,000-4,849,168,000-24,113,048,000-21,743,561,000-16,058,108,000-16,523,246,970

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

GeneOne Life Science, Inc., a biopharmaceutical firm headquartered in Seoul, South Korea, was founded in 1976. The company focuses on the innovation and manufacturing of gene-based biomedical products. Its developmental pipeline features several candidates: GLS-1027 is in Phase I for nephropathy and inflammatory conditions, and also in Phase II trials for COVID-19. Similarly, GLS-1200 is being tested in Phase II for both Rhinosinusitis and COVID-19. Other compounds under development include GLS-3000 and GLS-5310 for SARS-CoV-2, GLS-5100 targeting VZV-Shingles, and GLS-5140 for SFTS. The company is also advancing GLS-5300 in Phase II for MERS, GLS-5700 in Phase I for Zika, and GLS-6150 in Phase I for hepatitis C, alongside GLS-6100 which is in a pre-clinical stage for hepatitis C. Additionally, through its subsidiary VGXI, Inc., GeneOne Life Science offers contract manufacturing services for nucleic acid-based products, specifically DNA plasmids and mRNA, under cGMP standards. The company adopted its current name in April 2014, having previously been known as VGX International Inc.

Key people

Wu Geun Han
Co-Chief Executive Officer, Director · since 2025
Jeff Whitmore
Chief Marketing Officer · since 2024
Byeong Mun Cho
Managing Director · since 2010
Seong Ho Choi
Internal Auditor · since 2011
Yong Muk Kim
Internal Auditor · since 2025
Joel Maslow
Chief Medical Officer · since 2024
Yeong Geun Park
Chief Executive Officer, Director · since 2011
Jung Jin Sah
Director · since 2025
Sang Don Kim
Non-Executive Independent Director · since 2020
URL
https://www.genels.com/
IPO date
Nov 16, 1987
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT